Eocene subsidiary teams with Barcode Nanotech on nanoparticle Aramchol for GI cancers
Galmed R&D has built a new delivery form of Aramchol aimed at liver and gastrointestinal tumours, but the work is preclinical and no commercial terms were disclosed.
Eocene Ltd. said on 16 November 2026 that its subsidiary Galmed R&D, working with Barcode Nanotech, has created a lipid nanoparticle version of Aramchol. The pitch is a new use for an existing active substance, this time in oncology, though the announcement gives little basis for putting a commercial value on it.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): EoCene Ltd. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.